This dividend payout amounts to 120% of the stock’s face value of Rs 10 for the financial year ending March 31, 2025, offering shareholders a healthy return.
Over the past 52 weeks, Neuland Laboratories has recorded a high of Rs 18,089.55 and a low of Rs 7,900. While the stock is currently down around 23% from its 52-week high, it continues to trade significantly above its 52-week low, reflecting underlying strength and resilience in its price action.
The stock’s current 14-day Relative Strength Index (RSI) stands at 54.2. The RSI is a commonly used technical indicator that measures the strength and momentum of a stock’s price movements.
Values below 30 generally suggest the stock may be oversold (potentially undervalued), while values above 70 indicate it may be overbought (potentially overvalued). With an RSI near the middle range, the stock is currently neither oversold or overbought.
From a technical standpoint, Neuland Laboratories is demonstrating a strong bullish trend. The stock is trading above all eight Simple Moving Averages (SMAs) analyzed, covering periods from short-term (5-day) to long-term (200-day). This broad-based support from multiple moving averages suggests positive momentum and a generally favorable outlook among traders.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
